title: Coronary Artery Disease in the Human Immunodeficiency Virus Seropositive Population.
abstract: The development of efficient combined antiretroviral therapies has lengthened the mean life span of the population affected with human immunodeficiency virus (HIV) transforming this terminal infection to a chronic yet manageable disease. Nonetheless, patients with HIV--treatment naive or not--exhibit larger risks for coronary artery disease than the noninfected population. Moreover, coronary atherosclerosis/arteriosclerosis may be the most prevalent condition in the HIV-infected population that is being accentuated by the effects of viral agents and the antiretroviral drugs, especially protease inhibitors. Nonetheless, generalized metabolic dysfunctions and premature senescence are often attributed to the viremia caused by the HIV infection directly and primarily. Therefore, a multifactorial approach is to be considered when attempting to explain the strong correlation between HIV and coronary artery disease, including co-opportunistic viremias and vitamin D insufficiency/deficiency.
authors.affiliation: 1Chicago Medical School, North Chicago, IL; and 2Department of Medicine, Chicago Medical School, North Chicago, IL.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Barakat
authors.forename: Rohit R
authors.initials: RR
authors.lastname: Arora
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D019380:Anti-HIV Agents / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000209:etiology*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006679:HIV Seropositivity / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D009000:Monocytes / Q000502:physiology; D012307:Risk Factors; D014808:Vitamin D Deficiency / Q000150:complications
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors